As More Patients Gain Knowledge of Genetic Makeup, FDA Warns Against Biased Personalized Rx Trials | GenomeWeb

By Turna Ray

Online services that match patients to ongoing personalized drug trials based on the molecular characteristics of their disease may bias drug/diagnostic codevelopment studies and make the treatment and test appear more efficacious than they actually are, a US Food and Drug Administration biostatistics expert recently cautioned.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.